Letter to the Editor
Leukemia (2008) 22, 2261–2264; doi:10.1038/leu.2008.120; published online 29 May 2008
Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus
H Deng1, N Tang1, A E Stief1, N Mehta1, E Baig1, R Head1, G Sleep1, X-Z Yang2, C McKerlie3,4, S Trudel2,5, A K Stewart2 and J A McCart1,6,7,8
- 1Division of Experimental Therapeutics, Toronto General Research Institute, Toronto, Canada
- 2Department of Medical Oncology and Hematology, University Health Network, Toronto, Canada
- 3Centre For Modeling Human Disease, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada
- 4Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
- 5Department of Medicine, University of Toronto, Toronto, Canada
- 6Department of Surgery, Mount Sinai Hospital, Toronto, Canada
- 7Department of Surgical Oncology, University Health Network, Toronto, Canada
- 8Department of Surgery, University of Toronto, Toronto, Canada
Correspondence: JA McCart, E-mail: amccart@uhnres.utoronto.ca
Top of page
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Fighting Cancer with Vaccinia Virus: Teaching New Tricks to an Old Dog
Molecular Therapy Review
RESEARCH
An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy
Cell Research Research Article
Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells
Oncogene Original Article
Gene Therapy Original Article
Molecular Therapy Original Article
